The New York Times published an article on October 28th, 2012 citing another compounding pharmacy was ordered to shut down operations after a surprise inspection. Infusion Resource was immediately ordered to cease-and-desist after Massachusetts state officials found alarming environmental issues where medications were being compounded. These unannounced inspections started in the wake of the nationwide outbreak of fungal meningitis linked to a steroid made by the New England Compounding Pharmacy that has sickened more 363 people and killed a total of 28 people across 18 states.
This article points out several interesting facts about the compounding industry:
- Uncovering the problematic practices at compounding pharmacies where pharmacists prepare personalized medications is not a new issue of any sort. Citing the Food and Drug Administration records, Representative Edward J. Markey stated that there have been at least 23 deaths and 86 cases of serious illness associated with the unfit operations of these particular pharmacies (not including the statistics from the most recent fungal meningitis outbreak).
- Compounding pharmacies such as Infusion Resource are not subject to the same FDA oversight as regular drug manufacturers are and their operations essentially go unregulated.
- Due to the loopholes in state regulation and the incomplete and often unavailable information about the severe health risks caused by compounding pharmacies, government agencies have not been able to fully understand or even big to fix these complex issues.
The Columbus personal injury attorneys at Rourke and Blumenthal, LLP specialize in meningitis and infection cases caused by negligent contamination or failure to diagnose lethal infection at a preventative stage. To see our most recent bacterial meningitis verdicts and settlements click here or call our office at (614) 321-3212 for more information.